Cell lines, peripheral blood, and bone marrow blasts were treated with 25 [micro]mol/L Ara-C for 30 min at 37 [degrees]C and 5% C[O.sub.2].
Ara-C toxicity was also assayed with a 3-day cytotoxicity assay using the Cell Titer-Glo[R] Luminescent Cell Viability Assay kit (Promega, www.promega.
(15), expressing the human dCK gene, exhibited reduced relative growth in the presence of Ara-C in minimal medium but not in a rich growth medium, due to incorporation of cytosine triphosphate instead of the toxic analog Ara-CTP into bacterial DNA.
To measure Ara-C response in a nutrient-rich intracellular environment, an alternative cdd-deficient mutant of a bioluminescent E.
2, A and B) is similar to that observed with Ara-C (Fig.
AML cell lines and leukemic cell samples from AML patients with known clinical outcome to Ara-C treatment were used to evaluate the assay outlined by the schematic in Fig.
The 3-day cytotoxicity test also showed that cells from patient sample CR were significantly more sensitive to Ara-C compared with cells from patient sample NR (Fig.